Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval

 
• By Joseph Haas

Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.

Women's health
Myovant hopes second indication for Myfembree will spur women's health franchise • Source: Shutterstock

More from New Products

More from Scrip